Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: Experience from the placebo-controlled diabetic retinopathy candesartan trials

Diabetologia

Volumn 54, Issue 6, 2011, Pages 1298-1303

  Porta, M ^a   Hainer, J W ^b,j   Jansson, S O ^b   Malm, A ^b,j   Bilous, R ^c   Chaturvedi, N ^d   Fuller, J H ^e   Klein, R ^f   Orchard, T ^g   Parving, H H ^h   Sjolie A K ⁱ  

^a UNIVERSITY OF TURIN   (Italy)

^b ASTRAZENECA   (United Kingdom)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^h University Hospital of Copenhagen ^*  (Denmark)

ⁱ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^j ASTRAZENECA R AND D   (Sweden)

more..

Author keywords

Angiotensin receptor blockers; Pregnancy; Renin angiotensin system; Teratogenesis

Indexed keywords

CANDESARTAN; PLACEBO; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ARTICLE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFICACY; FEMALE; FETUS RISK; FIRST TRIMESTER PREGNANCY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; STILLBIRTH; ADOLESCENT; ADULT; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; HYPERTENSION; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; RISK FACTOR;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; BENZIMIDAZOLES; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; FEMALE; HUMANS; HYPERTENSION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; RISK FACTORS; TETRAZOLES; YOUNG ADULT;

EID: 80052535091     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-2040-1     Document Type: Article

References (14)

1. Schjoedt KJ, Hansen HP, Tarnow L, Rossing P, Parving HH (2008) Long-term prevention of diabetic nephropathy: an audit. Diabetologia 51:956-961
2. Alwan S, Polifka JE, Friedman JM (2005) Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Research (Part A) 73:123-1303.
3. Quan A (2006) Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Human Development 82:23-28
4. Cooper WO, Hernandez-Diaz S, Arbogast PG et al (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:2443-2451 (Pubitemid 43855047)
5. Lennestål R, Otterblad Olausson P, Källén B (2009) Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 65:615-625
6. Caton AR, Bell EM, Druschel CM et al (2009) Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 54:63-70
7. Yoder SR, Thornburg LL, Bisognano JD (2009) Hypertension in pregnancy and women of childbearing age. Am J Med 122:890-895
8. Allen VM, Armson BA, Wilson RD et al (2007) Teratogenicity associated with pre-existing and gestational diabetes. J Obstet Gynaecol Can 29:927-944
9. Chaturvedi N, Porta M, Klein R et al (2008) Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebocontrolled trials. Lancet 372:394-402
10. Sjølie AK, Klein R, Porta M et al (2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372:1385-1393
11. Food and Drug Administration (1992) Dangers of ACE inhibition during second and third trimesters of pregnancy. Med Bull 22:2
12. American Diabetes Association (2010) Standards of medical care in diabetes-2010. Diabetes Care 33(Suppl 1):S11-S61
13. Schultz S, Moullec J-M, Corvol P, Gasic J-M (1996) Early expression of all the components of the renin-angiotensin system in human development. Am J Pathology 149:2067-2079 (Pubitemid 26415223)
14. Haaland K (2010) Angiotensin II receptor antagonists against migraine in pregnacny: fatal outcome. J Headache Pain 11: 167-169